You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 14, 2025

BOEHRINGER INGELHEIM Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Drugs and US Patents for BOEHRINGER INGELHEIM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-001 Oct 15, 2014 RX Yes No 6,762,180*PED ⤷  Try for Free Y ⤷  Try for Free
Boehringer Ingelheim SYNJARDY XR empagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208658-001 Dec 9, 2016 RX Yes No 11,090,323*PED ⤷  Try for Free Y ⤷  Try for Free
Boehringer Ingelheim JENTADUETO linagliptin; metformin hydrochloride TABLET;ORAL 201281-002 Jan 30, 2012 AB RX Yes No 8,846,695*PED ⤷  Try for Free Y ⤷  Try for Free
Boehringer Ingelheim GILOTRIF afatinib dimaleate TABLET;ORAL 201292-003 Jul 12, 2013 RX Yes Yes ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BOEHRINGER INGELHEIM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim STIOLTO RESPIMAT olodaterol hydrochloride; tiotropium bromide SPRAY, METERED;INHALATION 206756-001 May 21, 2015 6,149,054*PED ⤷  Try for Free
Boehringer Ingelheim COMBIVENT RESPIMAT albuterol sulfate; ipratropium bromide SPRAY, METERED;INHALATION 021747-001 Oct 7, 2011 6,503,362 ⤷  Try for Free
Boehringer Ingelheim JENTADUETO linagliptin; metformin hydrochloride TABLET;ORAL 201281-001 Jan 30, 2012 8,178,541 ⤷  Try for Free
Boehringer Ingelheim COMBIVENT RESPIMAT albuterol sulfate; ipratropium bromide SPRAY, METERED;INHALATION 021747-001 Oct 7, 2011 5,405,084 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 20 mg, 40 mg and 80 mg ➤ Subscribe 2006-12-26
➤ Subscribe Tablets 80 mg/25 mg ➤ Subscribe 2009-02-27
➤ Subscribe Capsules 100 mg and 150 mg ➤ Subscribe 2018-10-15
➤ Subscribe Tablets 0.25 mg ➤ Subscribe 2005-05-27
➤ Subscribe Capsules eq. to 110 mg base ➤ Subscribe 2015-12-15
➤ Subscribe Oral Suspension 7.5 mg/5 mL ➤ Subscribe 2009-12-17
➤ Subscribe Extended-releaseTablets 2.5 mg/1000 mg 5 mg/1000 mg ➤ Subscribe 2018-03-28
➤ Subscribe Tablets 5 mg ➤ Subscribe 2015-05-04
➤ Subscribe Extended-release Tablets 2.25 mg and 3.75 mg ➤ Subscribe 2011-07-26
➤ Subscribe Extended-release Tablets 400 mg ➤ Subscribe 2013-06-21
➤ Subscribe Tablets 10 mg/5 mg and 25 mg/5 mg ➤ Subscribe 2018-08-01
➤ Subscribe Tablets 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg ➤ Subscribe 2015-05-04
➤ Subscribe Tablets 80 mg/12.5 mg and 40 mg/12.5 mg ➤ Subscribe 2008-12-31
➤ Subscribe Extended-release Capsules 25 mg and 200 mg ➤ Subscribe 2007-02-01
➤ Subscribe Tablets 0.125 mg, 0.5 mg, 1 mg and 1.5 mg ➤ Subscribe 2005-06-24
➤ Subscribe Capsules eq. to 75 mg base and 150 mg base ➤ Subscribe 2014-10-20
➤ Subscribe Tablets 0.75 mg ➤ Subscribe 2008-07-31
➤ Subscribe Inhalation Powder Capsules 18 mcg ➤ Subscribe 2018-05-11
➤ Subscribe Tablets 5 mg/500 mg5 mg/1000 mg12.5 mg/500 mg12.5 mg/1000 mg ➤ Subscribe 2018-08-01
➤ Subscribe Extended-release Tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg ➤ Subscribe 2010-06-01
➤ Subscribe Extended-release Tablets 5 mg/1000 mg10 mg/1000 mg12.5 mg/1000 mg25 mg/1000 mg ➤ Subscribe 2018-08-01
➤ Subscribe Tablets 20 mg, 30 mg and 40 mg ➤ Subscribe 2017-07-12
➤ Subscribe Tablets 10 mg and 25 mg ➤ Subscribe 2018-08-01

Supplementary Protection Certificates for BOEHRINGER INGELHEIM Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0443983 2007C/043 Belgium ⤷  Try for Free PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222
1870100 300538 Netherlands ⤷  Try for Free PRODUCT NAME: DABIGATRAN ETEXILAAT MESILAAT; REGISTRATION NO/DATE: EU/1/08/442/001-008 20080318
2525812 C02525812/01 Switzerland ⤷  Try for Free PRODUCT NAME: IDARUCIZUMABUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65804 20.07.2016
0503785 C300375 Netherlands ⤷  Try for Free PRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

BOEHRINGER INGELHEIM Market Analysis and Financial Projection

Pharmaceutical Competitive Landscape Analysis: Boehringer Ingelheim – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Boehringer Ingelheim stands out as a formidable player with a rich history and a strong commitment to innovation. As one of the top 20 companies in the global pharmaceutical industry, Boehringer Ingelheim has carved a niche for itself through its focus on research and development, strategic partnerships, and a diverse portfolio spanning human pharma, animal health, and biopharmaceutical contract manufacturing.

Company Overview and Market Position

Boehringer Ingelheim, founded in 1885, has maintained its status as a family-owned company for nearly 140 years. This unique ownership structure allows the company to pursue long-term strategies and invest heavily in research and development without the pressure of short-term shareholder demands.

Global Presence and Market Share

With operations in over 130 markets worldwide, Boehringer Ingelheim has established a strong global footprint. The company's net sales are primarily distributed across three main regions:

  • Americas: 47.7%
  • Europe: 32.3%
  • Asia/Australia/Africa: 20.0%[1]

This geographical diversification helps the company mitigate risks and capitalize on growth opportunities in emerging markets.

Business Segments

Boehringer Ingelheim's operations are divided into two main business areas:

  1. Human Pharma: Accounting for 81.1% of overall sales (20,774 million EUR in 2023)
  2. Animal Health: Contributing 18.5% of sales (4,724 million EUR in 2023)[1]

The company also generates a small portion of revenue (0.4%) from other sales, including discontinued operations.

Strengths and Competitive Advantages

Research and Development Focus

One of Boehringer Ingelheim's key strengths lies in its unwavering commitment to research and development. In 2023, the company invested 25.1% of its net sales in R&D for Human Pharma, positioning itself among the top R&D investors in the industry[1]. This significant investment enables Boehringer Ingelheim to maintain a robust pipeline of innovative drugs and therapies.

"Innovation is at the heart of Boehringer Ingelheim. In 2023 our investments in Research & Development (R&D) in Human Pharma grew to 25.1% of net sales, which ranks us among the top R&D investors in the industry."[1]

Diverse Product Portfolio

Boehringer Ingelheim boasts a diverse product portfolio across various therapeutic areas, including:

  • Cardiovascular diseases
  • Respiratory diseases
  • Oncology
  • Immunology
  • Metabolic diseases
  • Central nervous system disorders
  • Retinal health

This diversification helps the company spread risk and capitalize on multiple market opportunities.

Strong Market Position in Key Therapeutic Areas

The company has established a strong market position in several therapeutic areas, with flagship products like:

  • JARDIANCE®: A leading treatment for type-2 diabetes that also reduces cardiovascular risks
  • OFEV®: Used for treating idiopathic pulmonary fibrosis and other lung conditions

Animal Health Leadership

Boehringer Ingelheim is a market leader in Germany and the second-largest provider globally in animal health[6]. This position allows the company to leverage synergies between its human and animal health divisions, particularly in areas like immunology and infectious diseases.

Strategic Initiatives and Growth Drivers

Focus on Unmet Medical Needs

Boehringer Ingelheim's strategy revolves around addressing areas with high unmet medical needs. The company's long-term commitment allows it to invest in challenging research areas, such as mental health disorders like schizophrenia[1].

Digital Transformation and Data Analytics

Recognizing the importance of digital technologies in healthcare, Boehringer Ingelheim has been investing in digital capabilities to enhance customer experience and improve decision-making. The company has implemented a cloud-native analytics platform to process over 300 data feeds, enabling more than 60 reporting and analytics use cases across 23 business teams[4].

Strategic Partnerships and Collaborations

Boehringer Ingelheim actively seeks partnerships to bolster its pipeline and access cutting-edge technologies. Recent collaborations include:

  • Partnership with 3T Biosciences, Inc. for cancer therapy research
  • Collaboration with Carl Zeiss Meditec AG in eye diseases
  • Partnership with IBM in artificial intelligence applications[1]

Expansion of Global Innovation Capabilities

The company continues to invest in expanding its research and development facilities globally. For instance, in 2022, Boehringer Ingelheim announced a $57 million investment to increase laboratory space and bring additional R&D capabilities to its U.S. operations[3].

Market Challenges and Opportunities

Challenges

  1. Intense competition in key therapeutic areas
  2. Pricing pressures and healthcare reforms in major markets
  3. Regulatory hurdles and increasing costs of drug development
  4. Patent expirations of key products

Opportunities

  1. Growing demand for innovative treatments in areas like oncology and immunology
  2. Expansion in emerging markets, particularly in the Asia/Australia/Africa region
  3. Increasing focus on personalized medicine and targeted therapies
  4. Potential for cross-pollination of ideas between human and animal health divisions

Financial Performance and Outlook

Boehringer Ingelheim has demonstrated strong financial performance, with net sales reaching 25,611 million EUR in 2023[1]. The company's commitment to R&D investment and focus on high-growth therapeutic areas position it well for future growth.

Key Financial Highlights (2023)

  • Total net sales: 25,611 million EUR
  • Human Pharma sales: 20,774 million EUR (81.1% of total)
  • Animal Health sales: 4,724 million EUR (18.5% of total)
  • R&D investment in Human Pharma: 25.1% of net sales[1]

Competitive Landscape Analysis

Major Competitors

Boehringer Ingelheim competes with other top pharmaceutical companies, including:

  1. Pfizer
  2. Novartis
  3. Roche
  4. Merck & Co.
  5. Johnson & Johnson

Competitive Advantages

  1. Strong focus on R&D and innovation
  2. Diverse product portfolio across human and animal health
  3. Family ownership allowing for long-term strategic planning
  4. Strong market position in key therapeutic areas like diabetes and respiratory diseases

Areas for Improvement

  1. Expanding presence in emerging markets
  2. Accelerating digital transformation initiatives
  3. Enhancing pipeline in high-growth areas like oncology and rare diseases

Future Outlook and Strategic Direction

Boehringer Ingelheim's future strategy is likely to focus on:

  1. Continued investment in R&D to maintain a robust pipeline
  2. Expansion of digital capabilities and data analytics
  3. Strategic partnerships and collaborations to access new technologies
  4. Strengthening market position in key therapeutic areas
  5. Leveraging synergies between human and animal health divisions

Key Takeaways

  • Boehringer Ingelheim is a top 20 global pharmaceutical company with a strong focus on innovation and R&D.
  • The company's diverse portfolio spans human pharma, animal health, and biopharmaceutical contract manufacturing.
  • Significant R&D investment (25.1% of net sales in Human Pharma) positions the company as a leader in innovation.
  • Strong market position in key therapeutic areas like diabetes and respiratory diseases.
  • Strategic focus on addressing unmet medical needs and expanding digital capabilities.
  • Family ownership allows for long-term strategic planning and sustained R&D investment.
  • Challenges include intense competition, pricing pressures, and the need for continued pipeline expansion.
  • Future growth opportunities lie in emerging markets, personalized medicine, and cross-pollination between human and animal health divisions.

FAQs

  1. Q: What percentage of Boehringer Ingelheim's sales come from Human Pharma? A: In 2023, 81.1% of Boehringer Ingelheim's sales came from the Human Pharma business segment.

  2. Q: How much does Boehringer Ingelheim invest in R&D for Human Pharma? A: In 2023, Boehringer Ingelheim invested 25.1% of its net sales in R&D for Human Pharma.

  3. Q: What are Boehringer Ingelheim's main business areas? A: Boehringer Ingelheim's main business areas are Human Pharma and Animal Health, with a small portion of revenue from other sales.

  4. Q: What is Boehringer Ingelheim's global market position in Animal Health? A: Boehringer Ingelheim is the market leader in Germany and the second-largest provider globally in animal health.

  5. Q: How is Boehringer Ingelheim leveraging digital technologies? A: Boehringer Ingelheim has implemented a cloud-native analytics platform to process over 300 data feeds, enabling more than 60 reporting and analytics use cases across 23 business teams.

Sources cited: [1] https://annualreport.boehringer-ingelheim.com/2023/download/BOE_AR23_Highlights_2023_EN_safe.pdf [3] https://gov.georgia.gov/press-releases/2022-04-20/gov-kemp-boehringer-ingelheim-expands-global-innovation-capabilities [4] https://www.zs.com/about/case-studies/boehringer-ingelheim-powers-up-with-global-cloud-platform [6] https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_konzernlagebericht_2020_en.pdf

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.